Guardant Health, Inc. (GH) Insider Trading Activity

NASDAQ$170.3772-4.62 (-2.64%)
Market Cap
$23.48B
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
307 of 849
Rank in Industry
11 of 38

GH Insider Trading Activity

GH Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$78,456
1
2
Sells
$168,774,071
59
98

Related Transactions

Kalia KumudChief Information Officer
1
$78,456
7
$5.91M
$-5.83M
Azar Alex M IIdirector
0
$0
2
$155,582
$-155,582
POTTER MYRTLE Sdirector
0
$0
1
$204,085
$-204,085
Tariq Musadirector
0
$0
11
$422,188
$-422,188
Hidalgo Medina Manueldirector
0
$0
7
$1.03M
$-1.03M
Joyce Meghan V.director
0
$0
1
$1.27M
$-1.27M
Krognes Steve E.director
0
$0
2
$2.4M
$-2.4M
Saia John G.Chief Legal Officer
0
$0
3
$4.25M
$-4.25M
Chudova DaryaChief Technology Officer
0
$0
3
$4.36M
$-4.36M
CLARK IAN Tdirector
0
$0
3
$6.06M
$-6.06M
Bell Michael BrianChief Financial Officer
0
$0
3
$8.81M
$-8.81M
Monroe Terilyn J.Chief People Officer
0
$0
5
$15.95M
$-15.95M
Freeman ChrisChief Commercial Officer
0
$0
3
$16.92M
$-16.92M
Eltoukhy HelmyCo-Chief Executive Officer
0
$0
2
$22.03M
$-22.03M
Talasaz AmirAliCo-Chief Executive Officer
0
$0
6
$79M
$-79M

About Guardant Health, Inc.

Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico …

Insider Activity of Guardant Health, Inc.

Over the last 12 months, insiders at Guardant Health, Inc. have bought $78,456 and sold $168.77M worth of Guardant Health, Inc. stock.

On average, over the past 5 years, insiders at Guardant Health, Inc. have bought $6.16M and sold $41.76M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Kalia Kumud (Chief Information Officer) — $78,456.

The last purchase of 600 shares for transaction amount of $78,456 was made by Kalia Kumud (Chief Information Officer) on 2026‑06‑15.

List of Insider Buy and Sell Transactions, Guardant Health, Inc.

2026-10-16SaleTariq Musadirector
116
<0.0001%
$165.88
$19,242
+8.44%
2026-10-14SaleAzar Alex M IIdirector
69
<0.0001%
$159.89
$11,032
+4.24%
2026-09-16SaleTariq Musadirector
116
<0.0001%
$175.00
$20,300
-0.34%
2026-09-16SaleKrognes Steve E.director
6,674
0.005%
$175.74
$1.17M
-0.34%
2026-09-16SaleAzar Alex M IIdirector
826
0.0006%
$175.00
$144,550
-0.34%
2026-09-15SaleChudova DaryaChief Technology Officer
7,738
0.0058%
$178.00
$1.38M
-0.51%
2026-09-11SaleKalia KumudChief Information Officer
4,000
0.003%
$158.05
$632,193
+11.04%
2026-08-21SaleTalasaz AmirAliCo-Chief Executive Officer
37,500
0.0281%
$169.16
$6.34M
-1.27%
2026-08-17SaleTariq Musadirector
116
<0.0001%
$156.45
$18,148
+4.12%
2026-08-12SaleMonroe Terilyn J.Chief People Officer
46,300
0.0345%
$165.12
$7.65M
+1.67%
2026-08-10SaleFreeman ChrisChief Commercial Officer
63,605
0.0488%
$169.58
$10.79M
+0.27%
2026-08-05SaleHidalgo Medina Manueldirector
1,700
0.0013%
$164.24
$279,202
+2.63%
2026-08-04SaleCLARK IAN Tdirector
14,180
0.0105%
$158.92
$2.25M
+4.72%
2026-07-16SaleTariq Musadirector
116
<0.0001%
$163.29
$18,942
+6.40%
2026-06-29SaleTalasaz AmirAliCo-Chief Executive Officer
143,028
0.1063%
$151.54
$21.67M
+6.24%
2026-06-26SaleTalasaz AmirAliCo-Chief Executive Officer
116,972
0.0891%
$150.79
$17.64M
+9.41%
2026-06-22SalePOTTER MYRTLE Sdirector
1,556
0.0012%
$131.16
$204,085
+26.62%
2026-06-22SaleTariq Musadirector
1,951
0.0015%
$131.16
$255,893
+26.62%
2026-06-16SaleTariq Musadirector
116
<0.0001%
$130.19
$15,102
+28.00%
2026-06-15SaleKalia KumudChief Information Officer
600
0.0005%
$131.08
$78,648
+25.54%
Total: 323
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Eltoukhy HelmyCo-Chief Executive Officer
2012919
1.5%
$352.26M440
<0.0001%
Kalia KumudChief Information Officer
39794
0.0297%
$6.96M316
+22.77%
Talasaz AmirAliCo-Chief Executive Officer
37500
0.0279%
$6.56M460
<0.0001%
SOFTBANK VISION FUND (AIV M1) L.P.10 percent owner
27850460
20.7535%
$4.87B10
+5.91%
*Gray background shows insiders who have made transactions during last year

GH Institutional Investors: Active Positions

Increased Positions295+69.74%23M+18.38%
Decreased Positions186-43.97%16M-12.57%
New Positions138New5MNew
Sold Out Positions36Sold Out1MSold Out
Total Postitions532+25.77%131M+5.81%

GH Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$1.21M9.23%11.91M-259,191-2.13%2025-09-30
Blackrock, Inc.$1.16M8.86%11.43M+449,845+4.1%2025-09-30
Baillie Gifford & Co$521,691.003.98%5.13M+317,906+6.61%2025-09-30
Invesco Ltd.$501,532.003.82%4.93M+1M+38.53%2025-09-30
Capital International Investors$477,083.003.64%4.69M-287,217-5.77%2025-09-30
Price T Rowe Associates Inc /Md/$429,509.003.27%4.22M+2M+139.11%2025-09-30
Deep Track Capital, Lp$422,637.003.22%4.15M-95,914-2.26%2025-09-30
Eventide Asset Management, Llc$337,913.002.58%3.32M-137,625-3.98%2025-09-30
Wellington Management Group Llp$330,562.002.52%3.25M+1M+68.96%2025-09-30
Geode Capital Management, Llc$298,775.002.28%2.94M+15,942+0.55%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.